Dyne Therapeutics, Inc.
DYN
Positions held
Your positionsDYN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Dyne Therapeutics is positioned in the biotechnology sector, focusing on innovative therapies that address unmet medical needs, which can attract significant investor interest.
- The company's market cap stands at approximately $2.88 billion, indicating a substantial valuation in the biotech space.
- Dyne Therapeutics has a strong buy recommendation, with a target mean price of $36.0, suggesting potential upside for investors.
- The company has reported zero revenue for multiple quarters, indicating challenges in commercializing its products.
- In the most recent quarter, Dyne Therapeutics reported a net income loss of -178.556 million, continuing a trend of negative earnings.
- The company's operating income has consistently been negative, with a loss of -181.661 million in the latest quarter, reflecting ongoing financial difficulties.
Fundamentals
| Market cap | $3.06B | Enterprise value | $2.39B | Trailing P/E | — | Forward P/E | -4.91 |
| PEG | — | Price / book | 3.86 | Beta | 1.12 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -81.6% | ROA | -39.0% | Debt / equity | 0.33 |
| Current ratio | 12.02 | Free cash flow | -$317.14M | Analyst recommendation | strong_buy | Mean target | $35.73 |
| 52w high | $27.31 | 52w low | $13.73 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$179M | -$121M | -$112M | -$108M | -$111M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$182M | -$125M | -$116M | -$114M | -$116M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$446M | -$317M | -$236M | -$168M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$468M | -$344M | -$242M | -$171M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Top 4 Healthcare Stocks Backed by Raymond James Analysts
2026-10-07 · Why Dyne Therapeutics (DYN) Is Back In The Spotlight
2026-09-29 · Dyne Therapeutics stock rises on positive DM1 trial results
2026-09-17 · Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-17 · Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
2026-09-09 · Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says
2026-09-09 · Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
2026-09-09 · JPMorgan Downgrades Dyne Therapeutics to Underweight From Neutral, Cuts Price Target to $10 From $17
2026-09-09 · RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk
2026-09-08 · Novartis Stock Tanks Following Third Major Pipeline Setback
Price (daily)
Full chart · RSI · MACD · patterns